How to Buy Dyne Therapeutics Stock
Dyne Therapeutics Inc
Dyne Therapeutics, Inc. , a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Dyne Therapeutics stock last closed at $8.64, down 1.82% from the previous day, and has decreased 79.41% in one year. It has underperformed other stocks in the Biotechnology industry by 0.09 percentage points. Dyne Therapeutics stock is currently +35.85% from its 52-week low of $6.36, and -81.79% from its 52-week high of $47.45.
At the moment, there are 113.67M shares of DYN outstanding. The market value of DYN is $982.08M. In the past 24 hours, 2.64M DYN shares were traded.
How to Buy Dyne Therapeutics Stock
Wondering how to invest in Dyne Therapeutics stock? Here's how.
- Decide where to buy Dyne Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've analyzed dozens of online stock brokerages and apps to help you choose where to buy Dyne Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your payment method and add your information.
- Analyze Dyne Therapeutics stock: The Dyne Therapeutics ticker symbol is DYN. Is Dyne Therapeutics stock a good investment? Should you buy shares of DYN? How do DYN's underlying business fundamentals look? Do top analysts think Dyne Therapeutics is a good buy? Why has DYN's stock price moved recently? (Hint: Our stock research tools can help you decide if DYN is a good stock to buy).
- Make your DYN purchase: Decide if you will purchase DYN shares at the current market price or use a limit order to purchase DYN stock at a given price.
- Get the latest news on your investment in DYN: Create a watchlist to key updates about your new investment in Dyne Therapeutics shares.
Step 1: Decide where to buy Dyne Therapeutics stock
You need an online brokerage account to access the NASDAQ market and buy DYN stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to world markets: From Technology to Energy, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
- Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, you need to fill out some personal details so you are able to buy DYN stock today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start your new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have opened your account on app for stock, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your new brokerage account.
Step 4: Analyze Dyne Therapeutics stock
Once you have identified the best place to buy Dyne Therapeutics stock, it's critical to research their stock prior to investing, so you can understand the risk as well as the upside.
Dyne Therapeutics shares quick numbers
Dyne Therapeutics Fundamentals
WallStreetZen was created to help everyday investors do better fundamental analysis in less time.
You can see all of the due diligence checks on DYN's stock page.
Is DYN stock properly valued?
Analysts use many financial metrics, analyses, models, and charts to gauge DYN's fair value.
Using relative valuations ratios:
- DYN could be undervalued based on its P/B ratio of 1.47x, relative to Biotechnology industry P/B ratio of 4.62x
You can do additional valuation analysis on DYN's stock here.
DYN Financial Summary
Passed Health Checks:
- DYN has a low debt to equity ratio of 0.08.
- There are more short-term assets than short-term liabilities on the DYN balance sheet.
- DYN has cash burn of 322891000. It has enough cash and short-term investments to cover this for at least one year.
- DYN has $679.43M in cash and short term investments. This is enough to cover its annual cash burn of $322.89M.
- There are more short-term assets than long-term liabilities on the DYN balance sheet.
Is it a good time to buy Dyne Therapeutics stock, according to Wall Street analysts?
Out of 12 Wall Street analysts who give ratings on DYN, the consensus analyst rating on Dyne Therapeutics is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest DYN Analyst Forecasts
Andreas Argyrides, a top 5% analyst from Oppenheimer assumes DYN with a buy rating and lowers their DYN price target from $60.00 to $34.00, on Jun 2, 2025.
Andrew Fein, a top 4% analyst from HC Wainwright & Co. maintains DYN with a buy rating and lowers their DYN price target from $46.00 to $38.00, on May 9, 2025.
Tessa Romero, a top 19% analyst from JP Morgan maintains DYN with a hold rating and lowers their DYN price target from $18.00 to $17.00, on Mar 21, 2025.
Kostas Biliouris, a bottom 4% analyst from BMO Capital initiates coverage on DYN with a buy rating and announces their DYN price target of $50.00, on Mar 12, 2025.
Louise Chen, a bottom 6% analyst from ScotiaBank initiates coverage on DYN with a buy rating and announces their DYN price target of $50.00, on Mar 7, 2025.
You can dive deeper into what analysts are forecasting on the Dyne Therapeutics stock forecast page.
DYN Technicals
Latest Insiders Trades at DYN
Over the last 12 months, insiders at DYN have sold more shares than they have bought.
John Cox, CEO President of DYN, was the latest DYN insider to sell. They sold $54,201.00 worth of DYN stock on Jun 5, 2025.
Dig into more about who owns DYN stock here.
Can I rely on DYN as an income stream?
No, Dyne Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your DYN purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are usually fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact dollar amount limit, place a limit order.
Click the Open button and your broker will execute your order.
If you require additional assistance buying stocks on eToro, click the helpful video below:
Step 6: Get the latest news on your investment in DYN
Now that you own some DYN shares, you'll want to stay up-to-date on your investment.
Create a watchlist to track the latest developments regarding your DYN stock.
DYN Feed
How to Buy Stock in Dyne Therapeutics
To reiterate, here are the 6 steps you need to take to buy Dyne Therapeutics stock right now:
- Decide where to buy Dyne Therapeutics stock
- Open your brokerage account
- Fund your brokerage account
- Analyze Dyne Therapeutics stock
- Make your DYN purchase
- Get the latest news on your investment in DYN
If you require a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep an eye on your investment in Dyne Therapeutics, click the button below.
Other Stock Buying Guides You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.